sanofi-aventis (SNY) To Reduce U.S. Workforce by 25%; Will Refocus U.S. Ops on Three Areas
Tweet Send to a Friend
Up)
Sanofi-aventis' (NYSE: SNY) U.S. division announced that they would be streamlining their operations in lieu of the challenging healthcare marketplace.
The restructuring will include an estimated 25% work force reduction in U.S. Pharmaceutical Operations, eliminating approximately 1,700 positions in total. These decisions will be finalized by mid-December.
Also, the focus of U.S. Pharmaceuticals will be Diabetes, Atrial Fibrillation and Oncology.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The restructuring will include an estimated 25% work force reduction in U.S. Pharmaceutical Operations, eliminating approximately 1,700 positions in total. These decisions will be finalized by mid-December.
Also, the focus of U.S. Pharmaceuticals will be Diabetes, Atrial Fibrillation and Oncology.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
- Microsoft (MSFT) Flat Into Reveal of Next-Gen Xbox
- 3D Systems (DDD) Launches Cubify Draw on Apple (AAPL) iOS
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
